• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Verastem Inc.

    11/14/24 4:36:17 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VSTM alert in real time by email
    SC 13G 1 alyeska-vstm093024.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*



    Verastem, Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

     

    92337C203

    (CUSIP Number)

     

     

    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  92337C203
     SCHEDULE 13G
    Page 2 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Alyeska Investment Group, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    2,859,954
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    2,859,954
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,859,954
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    7.11%*
    12
    TYPE OF REPORTING PERSON
     
    IA

     The reporting persons are the beneficial owners of 2,859,954 shares of Common Stock of the Issuer, which constitute approximately 7.11% of the Issuer’s outstanding Common Stock shares. The percentage calculation assumes that there are currently 40,243,745 outstanding shares of Common Stock of the Issuer, based on the Issuer’s Quarterly Report Form 10-Q filed with the Securities and Exchange Commission on August 8, 2024.

     


     

    CUSIP No.  92337C203
     SCHEDULE 13G
    Page 3 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Alyeska Fund GP, LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    2,859,954
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    2,859,954
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,859,954
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    7.11%*
    12
    TYPE OF REPORTING PERSON
     
    OO

     The reporting persons are the beneficial owners of 2,859,954 shares of Common Stock of the Issuer, which constitute approximately 7.11% of the Issuer’s outstanding Common Stock shares. The percentage calculation assumes that there are currently 40,243,745 outstanding shares of Common Stock of the Issuer, based on the Issuer’s Quarterly Report Form 10-Q filed with the Securities and Exchange Commission on August 8, 2024.

     


     

    CUSIP No.  92337C203
     SCHEDULE 13G
    Page 4 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Anand Parekh
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States of America
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    2,859,954
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    2,859,954
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    2,859,954
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    7.11%*
    12
    TYPE OF REPORTING PERSON
     
    IN
    The reporting persons are the beneficial owners of 2,859,954 shares of Common Stock of the Issuer, which constitute approximately 7.11% of the Issuer’s outstanding Common Stock shares. The percentage calculation assumes that there are currently 40,243,745 outstanding shares of Common Stock of the Issuer, based on the Issuer’s Quarterly Report Form 10-Q filed with the Securities and Exchange Commission on August 8, 2024.
     


     

     

    CUSIP No. 92337C203
     SCHEDULE 13G
    Page 5 of 9 Pages

     

    Item 1.(a) Name of Issuer

    Verastem, Inc.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    4720 East Cotton Gin Loop, Suite 220

    Phoenix, Arizona 85040

    Item 2.(a) Names of Person Filing:

    (i) Alyeska Investment Group, L.P.

     

    (ii) Alyeska Fund GP, LLC

     

    (iii) Anand Parekh

      

    Item 2.(b) Address of Principal Business Office:

    (i) 77 West Wacker Drive, 7th Floor

    Chicago, IL 60601

     

    (ii) 77 West Wacker Drive, 7th Floor

    Chicago, IL 60601

     

    (iii) 77 West Wacker Drive, 7th Floor

    Chicago, IL 60601

      

    Item 2.(c) Citizenship:

    (i) Alyeska Investment Group, L.P. - Delaware

     

    (ii) Alyeska Fund GP, LLC - Delaware

     

    (iii) Anand Parekh - United States of America

      

    Item 2.(d) Title of Class of Securities

    Common Stock, $0.0001 par value per share

     

    Item 2.(e) CUSIP No.:

    92337C203

     

    CUSIP No.  92337C203
     SCHEDULE 13G
    Page 6 of 9 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) x A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

    CUSIP No. 92337C203
     SCHEDULE 13G
    Page 7 of 9 Pages

     

     

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount beneficially owned: Please refer to items 5-9 of the cover pages attached hereto

    (b) Percent of class: Please refer to item 11 of the cover pages attached hereto

    (c) Number of shares as to which the person has: Please refer to items 5-8 of the cover pages attached hereto

     The reporting persons are the beneficial owners of 1,859,954 shares of Common Stock of the Issuer and hold warrants to purchase 1,000,000 shares of the Issuer’s Common Stock (the “Warrants”) as of September 30, 2024. The percentage calculation assumes that there are currently 40,243,745 outstanding shares of Common Stock of the Issuer, based on the Issuer’s Quarterly Report Form 10-Q filed with the Securities and Exchange Commission on August 8, 2024.

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    Not Applicable.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 92337C203
     SCHEDULE 13G
    Page 8 of 9 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

     

     

     

    Alyeska Investment Group, L.P.

           
      By:  /s/ Jason Bragg
        Jason Bragg, Chief Financial Officer
           
     

    Alyeska Fund GP, LLC

           
      By:  /s/ Jason Bragg
        Jason Bragg, Chief Financial Officer
     

     

    Anand Parekh

    By:  Entity and Description

           
      By:  /s/ Anand Parekh
        Anand Parekh, Individually
           

     

     
    CUSIP No. 92337C203
     SCHEDULE 13G
    Page 9 of 9 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: November 14, 2024

     

     

    Alyeska Investment Group, L.P.

           
      By:  /s/ Jason Bragg
        Jason Bragg, Chief Financial Officer
           
     

    Alyeska Fund GP, LLC

           
      By:  /s/ Jason Bragg
        Jason Bragg, Chief Financial Officer
     

     

    Anand Parekh

           
      By:  /s/ Anand Parekh
        Anand Parekh, Individually
           
    Get the next $VSTM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VSTM

    DatePrice TargetRatingAnalyst
    4/10/2025$15.00Buy
    Jefferies
    3/24/2025$7.00 → $10.00Buy
    H.C. Wainwright
    12/31/2024$13.00 → $20.00Buy
    BTIG Research
    9/30/2024$13.00Buy
    Guggenheim
    11/21/2023$27.00Buy
    BTIG Research
    9/27/2023$21.00Buy
    B. Riley Securities
    6/15/2023$24.00 → $36.00Neutral → Buy
    Mizuho
    9/7/2022$6.00Buy
    Alliance Global Partners
    More analyst ratings

    $VSTM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Jefferies initiated coverage on Verastem with a new price target

      Jefferies initiated coverage of Verastem with a rating of Buy and set a new price target of $15.00

      4/10/25 12:44:18 PM ET
      $VSTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright reiterated coverage on Verastem with a new price target

      H.C. Wainwright reiterated coverage of Verastem with a rating of Buy and set a new price target of $10.00 from $7.00 previously

      3/24/25 7:46:47 AM ET
      $VSTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research reiterated coverage on Verastem with a new price target

      BTIG Research reiterated coverage of Verastem with a rating of Buy and set a new price target of $20.00 from $13.00 previously

      12/31/24 7:57:33 AM ET
      $VSTM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VSTM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Verastem Inc.

      SC 13G/A - Verastem, Inc. (0001526119) (Subject)

      11/14/24 6:25:40 PM ET
      $VSTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Verastem Inc.

      SC 13G/A - Verastem, Inc. (0001526119) (Subject)

      11/14/24 4:38:53 PM ET
      $VSTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Verastem Inc.

      SC 13G - Verastem, Inc. (0001526119) (Subject)

      11/14/24 4:36:17 PM ET
      $VSTM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VSTM
    Financials

    Live finance-specific insights

    See more
    • FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer

      AVMAPKI plus FAKZYNJA to be commercially available by prescription as a convenient oral combination co-packaged together and will be known as "AVMAPKI FAKZYNJA CO-PACK" Accelerated approval, well ahead of the June 30, 2025 PDUFA action date, was based on the Phase 2 RAMP 201 study that demonstrated a 44% overall response rate in patients with KRAS mutant recurrent LGSOC Verastem to host investor conference call and webcast today at 2:30 pm ET Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the U.S. Food and Drug Administration (FDA) has approved AVMAPKI™ FAKZYNJA™ CO-

      5/8/25 1:17:00 PM ET
      $VSTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting

      Robust overall response rates observed (31% overall, 44% in KRAS mutant, 17% in KRAS wild-type) in patients whose cancer had progressed despite prior treatment with chemotherapy and/or MEK inhibitors and/or bevacizumab Patients on avutometinib and defactinib achieved a median progression free survival of more than one year (12.9 months); 22 months in KRAS mutant population The Company recently met with the FDA to review the mature data set and remains on track to complete the NDA submission in October 2024 Additional data to be presented at the IGCS meeting and during Company-hosted investor conference call and webcast today, October 17, 2024 at 4:30 pm EDT Verastem Oncology (NASDAQ:VST

      10/17/24 1:00:00 AM ET
      $VSTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verastem Oncology Announces Details for the Oral Presentation of the Mature RAMP 201 Data Evaluating Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer at the IGCS 2024 Annual Meeting

      Company to host investor conference call and webcast on October 17, 2024, at 4:30 pm EDT Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced further details for its late-breaking presentation of mature data from the ongoing Phase 2 RAMP 201 (ENGOT-ov60/GOG-3052) clinical trial to be presented as an oral presentation at a plenary session at the International Gynecologic Cancer Society (IGCS) Annual Global Meeting taking place October 16-18, 2024 in Dublin, Ireland. The late-breaking abstract is embargoed until the morning of the presentation at IGCS. The oral presentation will include updated safety and

      10/9/24 6:00:00 AM ET
      $VSTM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VSTM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor

      In the study in China, GFH375 demonstrated an ORR of 52% in patients with pancreatic ductal adenocarcinoma and an ORR of 42% with non-small cell lung cancer Company activating sites in the U.S. for VS-7375 to begin enrollment in the Phase 1/2a trial Company will host an R&D investor webcast on Monday, June 2, at 11:00 am CDT to review updated RAMP 205 data as well as updated data on GFH375 presented at the ASCO 2025 Annual Meeting Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive updated data from the dose escalation phase of the Phase 1/2 trial of GFH375 (known

      6/2/25 9:40:00 AM ET
      $VSTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verastem Oncology to Present at the Jefferies Global Healthcare Conference

      Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 4:20 pm ET in New York. A live webcast of the fireside chat can be accessed under "Events & Presentations" on the Company's website at www.verastem.com. A replay of the webcasts will be archived on the website for approximately 90 days following the presentation. About Verastem Oncology Verastem Oncology (NASDAQ:VSTM) is a biopharmaceutical company committed to developing and

      5/28/25 7:30:00 AM ET
      $VSTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma

      Selected recommended Phase 2 dose: Dose level 1 demonstrated an ORR of 83% (10/12) in frontline metastatic pancreatic ductal adenocarcinoma Plans for registrational Phase 3 study underway in frontline metastatic pancreatic ductal adenocarcinoma Company will host an R&D investor webcast on Monday, June 2 at 11:00 am CDT to review the updated RAMP 205 data as well as updated data on VS-7375 presented at ASCO Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced positive updated safety and efficacy results from the RAMP 205 Phase 1/2 trial evaluating avutometinib plus defactinib in

      5/22/25 5:01:00 PM ET
      $VSTM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VSTM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Robertson Michelle was granted 8,333 shares, increasing direct ownership by 100% to 16,666 units (SEC Form 4)

      4 - Verastem, Inc. (0001526119) (Issuer)

      5/27/25 5:52:57 PM ET
      $VSTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Bunn Paul A. was granted 8,333 shares, increasing direct ownership by 100% to 16,666 units (SEC Form 4)

      4 - Verastem, Inc. (0001526119) (Issuer)

      5/27/25 5:52:23 PM ET
      $VSTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Kapur Anil was granted 8,333 shares, increasing direct ownership by 100% to 16,666 units (SEC Form 4)

      4 - Verastem, Inc. (0001526119) (Issuer)

      5/27/25 5:48:07 PM ET
      $VSTM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VSTM
    Leadership Updates

    Live Leadership Updates

    See more
    • Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

      Avutometinib plus defactinib granted priority review by FDA in December 2024, under the accelerated approval pathway, for KRAS mutant recurrent LGSOC; PDUFA action date set for June 30, 2025 Filed an investigational new drug application in the U.S. for VS-7375, an oral KRAS G12D (ON/OFF) inhibitor RAMP 205 trial in 1L metastatic pancreatic cancer continues to progress with an additional dose cohort added and enrollment across all dose-level cohorts on track to complete in Q1 Company cash, cash equivalents, and investments of $88.8 million as of December 31, 2024; pro forma $151.3 million including debt refinancing and equity issuance with Oberland, and equity issuance under at-the-market

      3/20/25 4:01:00 PM ET
      $VSTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verastem Oncology Names Matthew E. Ros as Chief Operating Officer

      New executive leadership supports the company's transition to a fully integrated commercial-stage organization in a year of transformative growth with a potential new product launch in mid-2025. Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Matthew E. Ros as chief operating officer. In his role, Mr. Ros will report to Dan Paterson, president and chief executive officer, and will serve on the company's executive leadership team. "We are thrilled to welcome Matt to Verastem Oncology at an important time as we prepare for a mid-2025 product launch and th

      1/15/25 7:30:00 AM ET
      $VSTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Applied Therapeutics Appoints John H. Johnson as Executive Chairman

      Shoshana Shendelman Steps Down as CEO; Les Funtleyder Appointed Interim Chief Executive Officer Announces Business Updates NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the following leadership changes, effective immediately: John H. Johnson, a recognized leader in the pharmaceutical and biotechnology industry, has been named Executive Chairman;Dr. Shoshana Shendelman has stepped down as Chair and CEO; andLes Funtleyder, Applied Therapeutics' Chief Financial Officer, has been named Interim Chief Executive Officer. Mr. John

      12/20/24 7:00:00 AM ET
      $APLT
      $RVPH
      $VSTM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VSTM
    SEC Filings

    See more
    • Verastem Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Verastem, Inc. (0001526119) (Filer)

      6/2/25 12:01:30 PM ET
      $VSTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verastem Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Verastem, Inc. (0001526119) (Filer)

      6/2/25 9:40:22 AM ET
      $VSTM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Verastem Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Verastem, Inc. (0001526119) (Filer)

      5/23/25 7:12:39 AM ET
      $VSTM
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VSTM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Rowinsky Eric K bought $7,680 worth of shares (2,000 units at $3.84) (SEC Form 4)

      4 - Verastem, Inc. (0001526119) (Issuer)

      1/24/24 4:00:39 PM ET
      $VSTM
      Biotechnology: Pharmaceutical Preparations
      Health Care